Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01312376 · ClinicalTrials.gov registry record · Phase 1
Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer
A Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01312376 is a Phase 1 study that was terminated before completion, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 18 participants.
The verdict
NCT01312376, a Phase 1 study, was terminated before completion, sponsored by Abramson Cancer Center at Penn Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a phase-I clinical trial to determine the feasibility and safety of Cyclophosphamide/Fludarabine Lymphodepletion and an immunomodulatory combination of Interferon-alpha Bevacizumab and Aspirin followed by adoptive transfer of vaccine-primed ex vivo CD3/CD28-costimulated peripheral blood autologous T cells and vaccination with whole tumor vaccine administered intradermally in combination with Bevacizumab in patients with recurrent ovarian cancer fallopian tube or primary peritoneal cancer. (Funding Source - FDA OOPD)
Interventions
- DRUG Bevacizumab
- BIOLOGICAL OC-DC vaccine
- DRUG cyclophosphamide 300 mg/m2/d for 3 days
- DRUG fludarabine 30 mg/m2/d for 3 days
- DRUG ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-03 |
| Est. Completion | 2019-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01312376
The ClinicalTrials.gov registry entry for NCT01312376 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT01312376 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01312376 about?
NCT01312376 is a clinical study titled "Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer". This is a phase-I clinical trial to determine the feasibility and safety of Cyclophosphamide/Fludarabine Lymphodepletion and an immunomodulatory combination of Interferon-alpha Bevacizumab and Aspirin followed by adoptive transfer of vaccine-primed ex vivo CD3/CD28-costimulated peripheral blood auto...
What is the current status of trial NCT01312376?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2011-03. Estimated completion is 2019-01.
What interventions are being tested in trial NCT01312376?
The interventions under investigation include: Bevacizumab (DRUG), OC-DC vaccine (BIOLOGICAL), cyclophosphamide 300 mg/m2/d for 3 days (DRUG), fludarabine 30 mg/m2/d for 3 days (DRUG), ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells (DRUG).
Who is sponsoring clinical trial NCT01312376?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.